# The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

> **NCT04751071** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Sadat City University**

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Roflumilast 500Mcg Tab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04751071
- **Lead sponsor:** Sadat City University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Institutional and funding constrains
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04751071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04751071, "The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04751071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*